Free Trial
NASDAQ:REVB

Revelation Biosciences (REVB) Stock Price, News & Analysis

Revelation Biosciences logo
$2.64 -0.03 (-0.94%)
As of 10:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Revelation Biosciences Stock (NASDAQ:REVB)

Key Stats

Today's Range
$2.67
$2.79
50-Day Range
$2.60
$5.16
52-Week Range
$2.36
$60.80
Volume
15,592 shs
Average Volume
113,004 shs
Market Capitalization
$2.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Remove Ads

Revelation Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

REVB MarketRank™: 

Revelation Biosciences scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Revelation Biosciences.

  • Earnings Growth

    Earnings for Revelation Biosciences are expected to grow in the coming year, from ($49.33) to ($34.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revelation Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revelation Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Revelation Biosciences has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Revelation Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.60% of the float of Revelation Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Revelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Revelation Biosciences has recently decreased by 61.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Revelation Biosciences does not currently pay a dividend.

  • Dividend Growth

    Revelation Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.60% of the float of Revelation Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Revelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Revelation Biosciences has recently decreased by 61.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Revelation Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • Search Interest

    Only 1 people have searched for REVB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Revelation Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Revelation Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 12.80% of the stock of Revelation Biosciences is held by institutions.

  • Read more about Revelation Biosciences' insider trading history.
Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

REVB Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Headlines

REVB Stock Analysis - Frequently Asked Questions

Revelation Biosciences' stock was trading at $7.3760 on January 1st, 2025. Since then, REVB stock has decreased by 63.8% and is now trading at $2.67.
View the best growth stocks for 2025 here
.

Revelation Biosciences, Inc. (NASDAQ:REVB) posted its quarterly earnings results on Tuesday, January, 29th. The company reported $9,912.00 earnings per share for the quarter, missing the consensus estimate of $10,248.00 by $336.00. The firm had revenue of $22.79 million for the quarter, compared to analysts' expectations of $22.20 million.

Revelation Biosciences's stock reverse split on the morning of Tuesday, January 28th 2025. The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

Last Earnings
1/29/2019
Today
4/03/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:REVB
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$402.10 per share
Price / Book
0.01

Miscellaneous

Free Float
268,000
Market Cap
$2.42 million
Optionable
Not Optionable
Beta
0.17
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:REVB) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners